Alimentary Pharmacology & Therapeutics

Review article: gene therapy in gastroenterology and hepatology
pp. 823-836(14)
Authors: FORBES, S. J.; HODGSON, H. J. F.

Effects of oral cisapride on small bowel motility in irritable bowel syndrome
pp. 837-844(8)
Authors: EVANS, P. R.; BAK, Y.-T.; KELLOW, J. E.

Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease
pp. 845-852(8)
Authors: FRANCHIS, R. DE; OMODEI, P.; RANZI, T.; BRIGNOLA, C.; ROCCA, R.; PRADA, A.; PERA, A.; VECCHI, M.; PIANO, M. DEL; FERRARA, A.; BELLOLI, C.; PIODI, L.; FRAMARIN, L.; ASTEGIANO, M.; RICCIOLI, F. A.; MEUCCI, G.

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
pp. 853-858(6)
Authors: KRUIS, W.; SCHÜTZ, E.; FRIC, P.; FIXA, B.; JUDMAIER, G.; STOLTE, M.

Nicotine enemas for active ulcerative colitis—a pilot study
pp. 859-863(5)
Authors: GREEN, J. T.; THOMAS, G. A. O.; RHODES, J.; WILLIAMS, G. T.; EVANS, B. K.; RUSSELL, M. A. H.; FEYERABEND, C.; RHODES, P.; SANDBORN, W. J.

A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration
pp. 865-874(10)
Authors: COMPTON, R. F.; SANDBORN, W. J.; LAWSON, G. M.; SHEETS, A. J.; MAYS, D. C.; ZINS, B. J.; TREMAINE, W. J.; LIPSKY, J. J.; MAHONEY, D. W.; ZINSMEISTER, A. R.; OFFORD, K. P.; HURT, R. D.; EVANS, B. K.; GREEN, J.

Inhibition of intragastric acidity in healthy subjects dosed with ranitidine 75 mg: a comparative study with cimetidine and placebo
pp. 875-879(5)
Authors: GRIMLEY, C. E.; CONSTANTINIDES, S.; SNELL, C. C.; MILLS, J. G.; NWOKOLO, C. U.

Nocturnal intragastric acidity after over-the-counter doses of famotidine, ranitidine or placebo
pp. 881-885(5)
Authors: GRIMLEY, C. E.; COTTRELL, J.; MANN, S. G.; STAUFFER, L.; NWOKOLO, C. U.

A prospective follow-up study of 5669 users of lansoprazole in daily practice
pp. 887-897(11)
Authors: LEUFKENS, H.; CLAESSENS, A.; HEERDINK, E.; VAN EIJK, J.; LAMERS, C. B. H. W.

Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats
pp. 899-906(8)
Authors: GIRAUD, M.-N.; SANDUJA, S. K.; FELDER, T. B.; ILLICH, P. A.; DIAL, E. J.; LICHTENBERGER, L. M.

The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non-steroidal anti-inflammatory drugs
pp. 907-912(6)
Authors: LIPSCOMB, G. R.; CAMPBELL, F.; REES, W. D. W.

A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori
pp. 913-917(5)
Authors: LAINE, L.; FRANTZ, J. E.; BAKER, A.; NEIL, G. A.

Two omeprazole-based Helicobacter pylori eradication regimens for the treatment of duodenal ulcer disease in general practice
pp. 919-927(9)
Authors: COTTRILL, M. R. B.; KINNON, C. M c; MASON, I.; CHESTERS, S. A.; SLATCHER, G.; COPEMAN, M. B.; TURBITT, M. L.

The management of failed dual or triple therapy for Helicobacter pylori eradication
pp. 929-933(5)
Authors: RINALDI, V.; ZULLO, A.; PUGLIANO, F.; VALENTE, C.; DIANA, F.; ATTILI, A. F.

Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection
pp. 935-938(4)
Authors: GRAHAM, D. Y.; HOFFMAN, J.; EL-ZIMAITY, H. M. T.; GRAHAM, D. P.; OSATO, M.

Clarithromycin, amoxycillin and H₂-receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea
pp. 939-942(4)
Authors: BREUER, T.; KIM, J. G.; EL-ZIMAITY, H. M. T.; NIKAJIMA, S.; OTA, H.; OSATO, M.; GRAHAM, D. Y.

Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer
pp. 943-952(10)
Authors: WURZER, H.; RODRIGO, L.; STAMLER, D.; ARCHAMBAULT, A.; ROKKAS, T.; SKANDALIS, N.; FEDORAK, R.; BAZZOLI, F.; HENTSCHEL, E.; MORA, P.; ARCHIMANDRITIS, A.; MEGRAUD, F.

Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis
pp. 953-957(5)
Authors: BECKER, K.; BECKER, C.; FRIELING, T.; HÄUSSINGER, D.

Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole—comparison of 24-hour intragastric and oesophageal pH
pp. 959-965(7)
Authors: ARMBRECHT, U.; ABUCAR, A.; HAMEETEMAN, W.; SCHNEIDER, A.; STOCKBRÜGGER, R. W.

Effects of 3-days' intake of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility
pp. 967-971(5)
Authors: STACHER, G.; SCHNEIDER, C.; STEINRINGER, H.; HOLZÄPFEL, A.; GAUPMANN, G.; STACHER-JANOTTA, G.

Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease
pp. 973-980(8)
Authors: ROBINSON, M.; MATON, P. N.; RODRIGUEZ, S.; GREENWOOD, B.; HUMPHRIES, T. J.

Lack of dose-response with Pancrease MT for the treatment of exocrine pancreatic insufficiency in adults
pp. 981-986(6)
Authors: OPEKUN Jr, A. R.; SUTTON Jr, F. M.; GRAHAM, D. Y.

Tilidine does not affect human sphincter of Oddi motility—a randomized, controlled study
pp. 987-992(6)
Authors: WEHRMANN, T.; RAUSCH, D.; SEILER, K. U.; BRENNSCHEIDT, U.; CASPARY, W. F.

Haemodynamic responses to a combination of terlipressin and octreotide in portal hypertensive rats
pp. 993-997(5)
Authors: MOREAU, R.; CAILMAIL, S.; VALLA, D.; LEBREC, D.